Nitric oxide: Perspectives and emerging studies of a well known cytotoxin

International Journal of Molecular Sciences

Volumn 11, Issue 7, 2010, Pages 2715-2745

  Paradise, William A ^a,b   Vesper, Benjamin J ^a,b   Goel, Ajay ^c   Waltonen, Joshua D ^d   Altman, Kenneth W ^e   Kenneth Haines, III ^f   Radosevich, James A ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytotoxicity; Epigenetics; High NO adaptation; Nitric oxide; Oncogenetic

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; APC PROTEIN; BRCA1 PROTEIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; CYTOTOXIN; DEATH ASSOCIATED PROTEIN KINASE; DICKKOPF 1 PROTEIN; DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; HISTONE; INDUCIBLE NITRIC OXIDE SYNTHASE; MICRORNA; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; PROTEIN MLH1; REACTIVE NITROGEN SPECIES; SOMATOMEDIN BINDING PROTEIN 3; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; TRANSCRIPTION FACTOR HOXA9; UVOMORULIN;

BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CELL PROTECTION; CIGARETTE SMOKING; DISEASE FREE SURVIVAL; DNA METHYLATION; EPIGENETICS; GENE OVEREXPRESSION; LARYNGECTOMY; LARYNX CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MUTAGENESIS; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PROTEIN MODIFICATION; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; TUMOR GROWTH; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; UTERUS SURGERY; WART VIRUS;

CYTOTOXICITY; EPIGENETICS; HIGH NO ADAPTATION; NITRIC OXIDE; ONCOGENETIC;

ANIMALS; CYTOTOXINS; EPIGENESIS, GENETIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NITRIC OXIDE; REACTIVE NITROGEN SPECIES;

EID: 77955067714     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms11072715     Document Type: Review

References (190)

1. Furchgott, R.F.; Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288, 373-376.
2. Stuehr, D.J.; Marletta, M.A. Mammalian nitrate biosynthesis: Mouse macrophages produce nitrite and nitrate in response to escherichia coli lipopolysaccharide. Proc. Natl. Acad. Sci. USA 1985, 82, 7738-7742.
3. Jacklet, J.W. Nitric oxide signaling in invertebrates. Invert. Neurosci. 1997, 3, 1-14.
4. Wilson, I.D.; Neill, S.J.; Hancock, J.T. Nitric oxide synthesis and signalling in plants. Plant Cell Environ. 2008, 31, 622-631.
5. Illi, B.; Colussi, C.; Grasselli, A.; Farsetti, A.; Capogrossi, M.C.; Gaetano, C. No sparks off chromatin: Tales of a multifaceted epigenetic regulator. Pharmacol. Ther. 2009, 123, 344-352.
6. Bentz, B.G.; Simmons, R.L.; Haines, G.K., III; Radosevich, J.A. The yin and yang of nitricoxide: Reflections on the physiology and pathophysiology of no. Head Neck 2000, 22, 71-83.
7. Mocellin, S.; Bronte, V.; Nitti, D. Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities. Med. Res. Rev. 2007, 27, 317-352.
8. Stamler, J.S. Redox signaling: Nitrosylation and related target interactions of nitric oxide. Cell 1994, 78, 931-936.
9. Hibbs, J.B.; Vavrin, A.; Taintor, R.R. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J. Immunol. 1987, 138, 550-565.
10. Langrehr, J.M.; Hoffman, R.A.; Lancaster, J.R., Jr.; Simmons, R.L. Nitric oxide--a new endogenous immunomodulator. Transplantation 1993, 55, 1205-1212.
11. Garthwaite, J. Concepts of neural nitric oxide-mediated transmission. Eur. J. Neurosci. 2008, 27, 2783-2802.
12. Chen, J.; Zacharek, A.; Zhang, C.; Jiang, H.; Li, Y.; Roberts, C.; Lu, M.; Kapke, A.; Chopp, M. Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J. Neurosci. 2005, 25, 2366-2375.
13. Goud, A.P.; Goud, P.T.; Diamond, M.P.; Abu-Soud, H.M. Nitric oxide delays oocyte aging. Biochemistry 2005, 44, 11361-11368.
14. Stamler, J.S.; Meissner, G. Physiology of nitric oxide in skeletal muscle. Physiol. Rev. 2001, 81, 209-237.
15. Teixeira, C.C.; Agoston, H.; Beier, F. Nitric oxide, c-type natriuretic peptide and cgmp as regulators of endochondral ossification. Dev. Biol. 2008, 319, 171-178.
16. Hayashi, T.; Yano, K.; Matsui-Hirai, H.; Yokoo, H.; Hattori, Y.; Iguchi, A. Nitric oxide and endothelial cellular senescence. Pharmacol. Ther. 2008, 120, 333-339.
17. Spinetti, G.; Kraenkel, N.; Emanueli, C.; Madeddu, P. Diabetes and vessel wall remodelling: From mechanistic insights to regenerative therapies. Cardiovasc. Res. 2008, 78, 265-273.
18. Thomas, D.D.; Espey, M.G.; Ridnour, L.A.; Hofseth, L.J.; Mancardi, D.; Harris, C.C.; Wink, D.A. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc. Natl. Acad. Sci. USA 2004, 101, 8894-8899.
19. Ridnour, L.A.; Thomas, D.D.; Mancardi, D.; Espey, M.G.; Miranda, K.M.; Paolocci, N.; Feelisch, M.; Fukuto, J.; Wink, D.A. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol. Chem. 2004, 385, 1-10.
20. Yu, Z.; Kuncewicz, T.; Dubinsky, W.P.; Kone, B.C. Nitric oxide-dependent negative feedback of parp-1 trans-activation of the inducible nitric-oxide synthase gene. J. Biol. Chem. 2006, 281, 9101-9109.
21. Mocellin, S. Nitric oxide: Cancer target or anticancer agent? Curr. Cancer Drug Targets 2009, 9, 214-236.
22. Ng, Q.S.; Goh, V.; Milner, J.; Stratford, M.R.; Folkes, L.K.; Tozer, G.M.; Saunders, M.I.; Hoskin, P.J. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: A phase I study. Lancet Oncol. 2007, 8, 111-118.
23. Gratton, J.P.; Lin, M.I.; Yu, J.; Weiss, E.D.; Jiang, Z.L.; Fairchild, T.A.; Iwakiri, Y.; Groszmann, R.; Claffey, K.P.; Cheng, Y.C., et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 2003, 4, 31-39.
24. Murohara, T.; Asahara, T.; Silver, M.; Bauters, C.; Masuda, H.; Kalka, C.; Kearney, M.; Chen, D.; Symes, J.F.; Fishman, M.C., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 1998, 101, 2567-2578.
25. Papapetropoulos, A.; Garcia-Cardena, G.; Madri, J.A.; Sessa, W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 1997, 100, 3131-3139.
26. Crowell, J.A.; Steele, V.E.; Sigman, C.C.; Fay, J.R. Is inducible nitric oxide synthase a target for chemoprevention? Mol. Cancer Ther. 2003, 2, 815-823.
27. Hofseth, L.J.; Hussain, S.P.; Wogan, G.N.; Harris, C.C. Nitric oxide in cancer and chemoprevention. Free Radic. Biol. Med. 2003, 34, 955-968.
28. Tozer, G.M.; Prise, V.E.; Chaplin, D.J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with l-arginine. Cancer Res. 1997, 57, 948-955.
29. Haynes, W.G.; Noon, J.P.; Walker, B.R.; Webb, D.J. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J. Hypertens. 1993, 11, 1375-1380.
30. Lorente, J.A.; Landin, L.; De Pablo, R.; Renes, E.; Liste, D. L-arginine pathway in the sepsis syndrome. Crit. Care Med. 1993, 21, 1287-1295.
31. Bentz, B.G.; Haines, G.K., III; Radosevich, J.A. Increased protein nitrosylation in head and neck squamous cell carcinoma. Head Neck 2000, 22, 64-70.
32. Jenkins, D.C.; Charles, I.G.; Thomsen, L.L.; Moss, D.W.; Holmes, L.S.; Baylis, S.A.; Rhodes, P.; Westmore, K.; Emson, P.C.; Moncada, S. Roles of nitric oxide in tumor growth. Proc. Natl. Acad. Sci. USA 1995, 92, 4392-4396.
33. Epperlein, M.M.; Nourooz-Zadeh, J.; Noronha-Dutra, A.A.; Woolf, N. Nitric oxide in cigarette smoke as a mediator of oxidative damage. Int. J. Exp. Pathol. 1996, 77, 197-200.
34. Gaston, B.; Drazen, J.M.; Loscalzo, J.; Stamler, J.S. The biology of nitrogen oxides in the airways. Am. J. Respir. Crit. Care Med. 1994, 149, 538-551.
35. Mirvish, S.S. Role of n-nitroso compounds (noc) and n-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to noc. Cancer Lett. 1995, 93, 17-48.
36. Gibson, Q.H.; Roughton, F.J. The determination of the velocity constants of four successive reactions of carbon monoxide with sheep haemoglobin. Proc. Soc. Ser. B: Biol. Sci. Lond. 1957, 206-224.
37. Davis, K.L.; Martin, E.; Turko, I.V.; Murad, F. Novel effects of nitric oxide. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 203-236.
38. Souza, J.M.; Peluffo, G.; Radi, R. Protein tyrosine nitration--functional alteration or just a biomarker? Free Radic. Biol. Med. 2008, 45, 357-366.
39. Lane, A.P.; Prazma, J.; Baggett, H.C.; Rose, A.S.; Pillsbury, H.C. Nitric oxide is a mediator of neurogenic vascular exudation in the nose. Otolaryngol. Head Neck. Surg. 1997, 116, 294-300.
40. Michel, O.; Bloch, W.; Rocker, J. Nos-mapping of human nasal mucosa under physiologic and pathophysiological conditions. In Proceedings of the Fourth International Meeting on the Biology of Nitric Oxide. Moncada, S., Stamler, J., Gross, S., Higgs, E.A., Eds.; Portland Press: London, UK, 1996; p. 230.
41. Eaton, D.L.; Bammler, T.K. Concise review of the glutathione s-transferases and their significance to toxicology. Toxicol. Sci. 1999, 49, 156-164.
42. Hanna, E.; MacLeod, S.; Vural, E.; Lang, N. Genetic deletions of glutathione-s-transferase as a risk factor in squamous cell carcinoma of the larynx: A preliminary report. Am. J. Otolaryngol. 2001, 22, 121-123.
43. Ketterer, B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat. Res. 1988, 202, 343-361.
44. Mulder, T.P.; Manni, J.J.; Roelofs, H.M.; Peters, W.H.; Wiersma, A. Glutatione s-transferases and glutathione in human head and neck cancer. Carcinogenesis 1995, 16, 619-624.
45. McIlwain, C.C.; Townsend, D.M.; Tew, K.D. Glutathione s-transferase polymorphisms: Cancer incidence and therapy. Oncogene 2006, 25, 1639-1648.
46. Schumaker, L.; Nikitakis, N.; Goloubeva, O.; Tan, M.; Taylor, R.; Cullen, K.J. Elevated expression of glutathione s-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin. Cancer Res. 2008, 14, 5877-5883.
47. Ali-Osman, F.; Akande, O.; Antoun, G.; Mao, J.X.; Buolamwini, J. Molecular cloning, characterization, and expression in escherichia coli of full-length cdnas of three human glutathione s-transferase pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J. Biol. Chem. 1997, 272, 10004-10012.
48. Goto, S.; Iida, T.; Cho, S.; Oka, M.; Kohno, S.; Kondo, T. Overexpression of glutathione s- transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic. Res. 1999, 31, 549-558.
49. Stoehlmacher, J.; Park, D.J.; Zhang, W.; Groshen, S.; Tsao-Wei, D.D.; Yu, M.C.; Lenz, H.J. Association between glutathione s-transferase p1, t1, and m1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst. 2002, 94, 936-942.
50. Maugard, C.M.; Charrier, J.; Pitard, A.; Campion, L.; Akande, O.; Pleasants, L.; Ali-Osman, F. Genetic polymorphism at the glutathione s-transferase (gst) p1 locus is a breast cancer risk modifier. Int. J. Cancer 2001, 91, 334-339.
51. Tew, K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994, 54, 4313-4320.
52. Miura, K.; Suzuki, S.; Tanita, J.; Shinkawa, H.; Satoh, K.; Tsuchida, S. Correlated expression of glutathione s-transferase-pi and c-jun or other oncogene products in human squamous cell carcinomas of the head and neck: Relevance to relapse after radiation therapy. Jpn. J. Cancer Res. 1997, 88, 143-151.
53. Bongers, V.; Snow, G.B.; de Vries, N.; Cattan, A.R.; Hall, A.G.; van der Waal, I.; Braakhuis, B.J. Second primary head and neck squamous cell carcinoma predicted by the glutathione s- transferase expression in healthy tissue in the direct vicinity of the first tumor. Lab. Invest. 1995, 73, 503-510.
54. Bentz, B.G.; Haines, G.K., III; Lingen, M.W.; Pelzer, H.J.; Hanson, D.G.; Radosevich, J.A. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann. Otol. Rhinol. Laryngol. 1999, 108, 781-787.
55. Bentz, B.G.; Haines, G.K., III; Radosevich, J.A. Glutathione s-transferase pi in squamous cell carcinoma of the head and neck. Laryngoscope 2000, 110, 1642-1647.
56. Bentz, B.G.; Haines, G.K., III; Lingen, M.W.; Pelzer, H.J.; Hanson, D.G.; Radosevich, J.A. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann. Otol. Rhinol. Laryngol. 1999, 108, 781-787.
57. Bentz, B.G.; Haines, G.K., III; Radosevich, J.A. Glutathione s-transferase pi in squamous cell carcinoma of the head and neck. Laryngoscope 2000, 110, 1642-1647.
58. Wei, L.; Gravitt, P.E.; Song, H.; Maldonado, A.M.; Ozbun, M.A. Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. Cancer Res. 2009, 69, 4878-4884.
59. Benencia, F.; Gamba, G.; Cavalieri, H.; Courreges, M.C.; Benedetti, R.; Villamil, S.M.; Massouh, E.J. Nitric oxide and hsv vaginal infection in balb/c mice. Virology 2003, 309, 75-84.
60. Carratelli, C.R.; Rizzo, A.; Paolillo, R.; Catania, M.R.; Catalanotti, P.; Rossano, F. Effect of nitric oxide on the growth of chlamydophila pneumoniae. Can. J. Microbiol. 2005, 51, 941-947.
61. Chang, K.; Lubo, Z. Review article: Steroid hormones and uterine vascular adaptation to pregnancy. Reprod. Sci. 2008, 15, 336-348.
62. Hiraku, Y.; Tabata, T.; Ma, N.; Murata, M.; Ding, X.; Kawanishi, S. Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection. Cancer Sci. 2007, 98, 964-972.
63. Tavares-Murta, B.M.; de Resende, A.D.; Cunha, F.Q.; Murta, E.F. Local profile of cytokines and nitric oxide in patients with bacterial vaginosis and cervical intraepithelial neoplasia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 138, 93-99.
64. Cerutti, P.A. Prooxidant states and tumor promotion. Science 1985, 227, 375-381.
65. Hussain, S.P.; Harris, C.C. Inflammation and cancer: An ancient link with novel potentials. Int. J. Cancer 2007, 121, 2373-2380.
66. Hussain, S.P.; Raja, K.; Amstad, P.A.; Sawyer, M.; Trudel, L.J.; Wogan, G.N.; Hofseth, L.J.; Shields, P.G.; Billiar, T.R.; Trautwein, C., et al. Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: Oxyradical overload diseases. Proc. Natl. Acad. Sci. USA 2000, 97, 12770-12775.
67. Nair, J.; Gansauge, F.; Beger, H.; Dolara, P.; Winde, G.; Bartsch, H. Increased etheno-DNA adducts in affected tissues of patients suffering from crohn's disease, ulcerative colitis, and chronic pancreatitis. Antioxid. Redox. Signal 2006, 8, 1003-1010.
68. Cerutti, P.A.; Trump, B.F. Inflammation and oxidative stress in carcinogenesis. Cancer Cells 1991, 3, 1-7.
69. Shaulian, E.; Karin, M. Ap-1 as a regulator of cell life and death. Nat. Cell Biol. 2002, 4, E131-E136.
70. Hofseth, L.J.; Saito, S.; Hussain, S.P.; Espey, M.G.; Miranda, K.M.; Araki, Y.; Jhappan, C.; Higashimoto, Y.; He, P.; Linke, S.P., et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc. Natl. Acad. Sci. USA 2003, 100, 143-148.
71. Ying, L.; Marino, J.; Hussain, S.P.; Khan, M.A.; You, S.; Hofseth, A.B.; Trivers, G.E.; Dixon, D.A.; Harris, C.C.; Hofseth, L.J. Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and e2f1 activation. Cancer Res. 2005, 65, 9132-9136.
72. Wink, D.A.; Hanbauer, I.; Grisham, M.B.; Laval, F.; Nims, R.W.; Laval, J.; Cook, J.; Pacelli, R.; Liebmann, J.; Krishna, M., et al. Chemical biology of nitric oxide: Regulation and protective and toxic mechanisms. Curr. Top Cell Regul. 1996, 34, 159-187.
73. Xu, W.; Liu, L.; Smith, G.C.; Charles, G. Nitric oxide upregulates expression of DNA-pkcs to protect cells from DNA-damaging anti-tumour agents. Nat. Cell Biol. 2000, 2, 339-345.
74. Jablonka, E.; Lamb, M.J. The changing concept of epigenetics. Ann. NY Acad. Sci. 2002, 981, 82-96.
75. Peters, J. Overview of mammalian genome special issue on epigenetics. Mamm. Genome 2009, 20, 529-531.
76. Waddington, C.H. The epigenotype. Endeavour 1942, 18-20.
77. Das, P.M.; Singal, R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22, 4632-4642.
78. DeAngelis, J.T.; Farrington, W.J.; Tollefsbol, T.O. An overview of epigenetic assays. Mol. Biotechnol. 2008, 38, 179-183.
79. Jacob, S.; Moley, K.H. Gametes and embryo epigenetic reprogramming affect developmental outcome: Implication for assisted reproductive technologies. Pediatr. Res. 2005, 58, 437-446.
80. Tang, W.Y.; Ho, S.M. Epigenetic reprogramming and imprinting in origins of disease. Rev. Endocr. Metab. Disord. 2007, 8, 173-182.
81. Miller, C.A.; Sweatt, J.D. Covalent modification of DNA regulates memory formation. Neuron 2007, 53, 857-869.
82. Matouk, C.C.; Marsden, P.A. Epigenetic regulation of vascular endothelial gene expression. Circ. Res. 2008, 102, 873-887.
83. Prokhortchouk, E.; Defossez, P.A. The cell biology of DNA methylation in mammals. Biochim. Biophys. Acta 2008, 1783, 2167-2173.
84. Horn, P.J.; Peterson, C.L. Molecular biology. Chromatin higher order folding--wrapping up transcription. Science 2002, 297, 1824-1827.
85. Carthew, R.W.; Sontheimer, E.J. Origins and mechanisms of mirnas and sirnas. Cell 2009, 136, 642-655.
86. Luger, K.; Mader, A.W.; Richmond, R.K.; Sargent, D.F.; Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 a resolution. Nature 1997, 389, 251-260.
87. Hansen, J.C. Conformational dynamics of the chromatin fiber in solution: Determinants, mechanisms, and functions. Ann. Rev. Biophys. Biomol. Struct. 2002, 31, 361-392.
88. Jenuwein, T.; Allis, C.D. Translating the histone code. Science 2001, 293, 1074-1080.
89. Takai, D.; Jones, P.A. The cpg island searcher: A new www resource. In Silico Biol. 2003, 3, 235-240.
90. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8, 286-298.
91. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415-428.
92. Klose, R.J.; Bird, A.P. Genomic DNA methylation: The mark and its mediators. Trends Biochem. Sci. 2006, 31, 89-97.
93. Takai, D.; Jones, P.A. Comprehensive analysis of cpg islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA 2002, 99, 3740-3745.
94. Catteau, A.; Morris, J.R. Brca1 methylation: A significant role in tumour development? Semin. Cancer Biol. 2002, 12, 359-371.
95. Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429, 457-463.
96. Leone, G.; Teofili, L.; Voso, M.T.; Lubbert, M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002, 87, 1324-1341.
97. Tsou, J.A.; Hagen, J.A.; Carpenter, C.L.; Laird-Offringa, I.A. DNA methylation analysis: A powerful new tool for lung cancer diagnosis. Oncogene 2002, 21, 5450-5461.
98. Liu, J.; Casaccia, P. Epigenetic regulation of oligodendrocyte identity. Trends Neurosci. 2010, 33, 193-201.
99. Chuang, J.C.; Jones, P.A. Epigenetics and micrornas. Pediatr. Res. 2007, 61, 24R-29R.
100. Goel, A. Cpg island methylator phenotype in colrectal cancer: A current perspective. Curr. Colorect. Cancer Rep. 2008, 77-83.
101. Boland, R. Promoter methylation in the genesis of gastrointestinal cancer. Yonsei Med. J. 2009, 50, 309-321.
102. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10, 789-799.
103. Bedford, M.T.; van Helden, P.D. Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. 1987, 47, 5274-5276.
104. Ehrlich, M. DNA methylation in cancer: Too much, but also too little. Oncogene 2002, 21, 5400-5413.
105. Kim, Y.I.; Giuliano, A.; Hatch, K.D.; Schneider, A.; Nour, M.A.; Dallal, G.E.; Selhub, J.; Mason, J.B. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 1994, 74, 893-899.
106. Lin, C.H.; Hsieh, S.Y.; Sheen, I.S.; Lee, W.C.; Chen, T.C.; Shyu, W.C.; Liaw, Y.F. Genome- wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001, 61, 4238-4243.
107. Kawakami, K.; Brabender, J.; Lord, R.V.; Groshen, S.; Greenwald, B.D.; Krasna, M.J.; Yin, J.; Fleisher, A.S.; Abraham, J.M.; Beer, D.G., et al. Hypermethylated apc DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 2000, 92, 1805-1811.
108. Harden, S.V.; Tokumaru, Y.; Westra, W.H.; Goodman, S.; Ahrendt, S.A.; Yang, S.C.; Sidransky, D. Gene promoter hypermethylation in tumors and lymph nodes of stage i lung cancer patients. Clin. Cancer Res. 2003, 9, 1370-1375.
109. Virmani, A.K.; Rathi, A.; Sathyanarayana, U.G.; Padar, A.; Huang, C.X.; Cunnigham, H.T.; Farinas, A.J.; Milchgrub, S.; Euhus, D.M.; Gilcrease, M., et al. Aberrant methylation of the adenomatous polyposis coli (apc) gene promoter 1a in breast and lung carcinomas. Clin. Cancer Res. 2001, 7, 1998-2004.
110. Chan, K.Y.; Ozcelik, H.; Cheung, A.N.; Ngan, H.Y.; Khoo, U.S. Epigenetic factors controlling the brca1 and brca2 genes in sporadic ovarian cancer. Cancer Res. 2002, 62, 4151-4156.
111. Dobrovic, A.; Simpfendorfer, D. Methylation of the brca1 gene in sporadic breast cancer. Cancer Res. 1997, 57, 3347-3350.
112. Sanchez-Cespedes, M.; Esteller, M.; Wu, L.; Nawroz-Danish, H.; Yoo, G.H.; Koch, W.M.; Jen, J.; Herman, J.G.; Sidransky, D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000, 60, 892-895.
113. Villuendas, R. Loss of p16/ink4a protein expression in non-hodgkin's lymphomas is a frequent finding associated with tumor progression. Am. J. Pathol. 1998, 887-897.
114. Graff, J.R.; Herman, J.G.; Lapidus, R.G.; Chopra, H.; Xu, R.; Jarrard, D.F.; Isaacs, W.B.; Pitha, P.M.; Davidson, N.E.; Baylin, S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995, 55, 5195-5199.
115. Graff, J.R.; Greenberg, V.E.; Herman, J.G.; Westra, W.H.; Boghaert, E.R.; Ain, K.B.; Saji, M.; Zeiger, M.A.; Zimmer, S.G.; Baylin, S.B. Distinct patterns of e-cadherin cpg island methylation in papillary, follicular, hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res. 1998, 58, 2063-2066.
116. Waki, T.; Tamura, G.; Tsuchiya, T.; Sato, K.; Nishizuka, S.; Motoyama, T. Promoter methylation status of e-cadherin, hmlh1, and p16 genes in nonneoplastic gastric epithelia. Am. J. Pathol. 2002, 161, 399-403.
117. Yang, X.; Yan, L.; Davidson, N.E. DNA methylation in breast cancer. Endocr. Relat. Cancer 2001, 8, 115-127.
118. Li, L.C.; Chui, R.; Nakajima, K.; Oh, B.R.; Au, H.C.; Dahiya, R. Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression. Cancer Res. 2000, 60, 702-706.
119. Lee, W.H.; Morton, R.A.; Epstein, J.I.; Brooks, J.D.; Campbell, P.A.; Bova, G.S.; Hsieh, W.S.; Isaacs, W.B.; Nelson, W.G. Cytidine methylation of regulatory sequences near the pi-class glutathione s-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 1994, 91, 11733-11737.
120. Veigl, M.L.; Kasturi, L.; Olechnowicz, J.; Ma, A.H.; Lutterbaugh, J.D.; Periyasamy, S.; Li, G.M.; Drummond, J.; Modrich, P.L.; Sedwick, W.D., et al. Biallelic inactivation of hmlh1 by epigenetic gene silencing, a novel mechanism causing human msi cancers. Proc. Natl. Acad. Sci. USA 1998, 95, 8698-8702.
121. Kondo, E. Not hmsh2 but hmlh1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int. J. Oncol. 2000, 535-541.
122. Strathdee, G.; MacKean, M.J.; Illand, M.; Brown, R. A role for methylation of the hmlh1 promoter in loss of hmlh1 expression and drug resistance in ovarian cancer. Oncogene 1999, 18, 2335-2341.
123. Harden, S.V.; Tokumaru, Y.; Westra, W.H.; Goodman, S.; Ahrendt, S.A.; Yang, S.C.; Sidransky, D. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin. Cancer Res. 2003, 9, 1370-1375.
124. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene mgmt and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343, 1350-1354.
125. Melki, J.R.; Vincent, P.C.; Clark, S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999, 59, 3730-3740.
126. Garcia, M.J.; Martinez-Delgado, B.; Cebrian, A.; Martinez, A.; Benitez, J.; Rivas, C. Different incidence and pattern of p15ink4b and p16ink4a promoter region hypermethylation in hodgkin's and cd30-positive non-hodgkin's lymphomas. Am. J. Pathol. 2002, 161, 1007-1013.
127. Herman, J.G.; Jen, J.; Merlo, A.; Baylin, S.B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15ink4b. Cancer Res. 1996, 56, 722-727.
128. Agathanggelou, A. Methylation associated inactivation of rassf1a from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001, 1509-1518.
129. Morrissey, C.; Martinez, A.; Zatyka, M.; Agathanggelou, A.; Honorio, S.; Astuti, D.; Morgan, N.V.; Moch, H.; Richards, F.M.; Kishida, T., et al. Epigenetic inactivation of the rassf1a 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001, 61, 7277-7281.
130. Kwong, J.; Lo, K.W.; To, K.F.; Teo, P.M.; Johnson, P.J.; Huang, D.P. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 2002, 8, 131-137.
131. Stirzaker, C.; Millar, D.S.; Paul, C.L.; Warnecke, P.M.; Harrison, J.; Vincent, P.C.; Frommer, M.; Clark, S.J. Extensive DNA methylation spanning the rb promoter in retinoblastoma tumors. Cancer Res. 1997, 57, 2229-2237.
132. Gonzalez-Gomez, P.; Bello, M.J.; Alonso, M.E.; Arjona, D.; Lomas, J.; de Campos, J.M.; Isla, A.; Rey, J.A. Cpg island methylation status and mutation analysis of the rb1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br. J. Cancer 2003, 88, 109-114.
133. Tannenbaum, S.R.; White, F.M. Regulation and specificity of s-nitrosylation and denitrosylation. ACS Chem. Biol. 2006, 1, 615-618.
134. Sbaa, E.; Frerart, F.; Feron, O. The double regulation of endothelial nitric oxide synthase by caveolae and caveolin: A paradox solved through the study of angiogenesis. Trends Cardiovasc. Med. 2005, 15, 157-162.
135. 2+ complex. Biopolymers 1967, 5, 615-625.
136. Robbins, E.; Fant, J.; Norton, W. Intracellular iron-binding macromolecules in hela cells. Proc. Natl. Acad. Sci. USA 1972, 69, 3708-3712.
137. Bitny-Szlachto, S.; Ochalska-Czepulis, M. Effects of disulphides and alpha-oxoglutarate on nuclear thiol formation and thiol content of chromatin in lysed rat spleen nuclei. Int. J. Biochem. 1978, 9, 179-183.
138. Vanin, A.F.; Ivanov, V.I. Interaction of iron ions with oxygen or nitrogen monoxide in chromosomes triggers synchronous expression/suppression oscillations of compact gene groups (Genomewide oscillation): Hypothesis. Nitric Oxide 2008, 18, 147-152.
139. Elzaouk, L.; Laufs, S.; Heerklotz, D.; Leimbacher, W.; Blau, N.; Resibois, A.; Thony, B. Nuclear localization of tetrahydrobiopterin biosynthetic enzymes. Biochim. Biophys. Acta 2004, 1670, 56-68.
140. Calin, G.A.; Croce, C.M. Microrna signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
141. Nilsen, T.W. Mechanisms of microrna-mediated gene regulation in animal cells. Trends Genet. 2007, 23, 243-249.
142. Farh, K.K.; Grimson, A.; Jan, C.; Lewis, B.P.; Johnston, W.K.; Lim, L.P.; Burge, C.B.; Bartel, D.P. The widespread impact of mammalian micrornas on mrna repression and evolution. Science 2005, 310, 1817-1821.
143. Lewis, B.P.; Shih, I.H.; Jones-Rhoades, M.W.; Bartel, D.P.; Burge, C.B. Prediction of mammalian microrna targets. Cell 2003, 115, 787-798.
144. Stark, A.; Brennecke, J.; Bushati, N.; Russell, R.B.; Cohen, S.M. Animal micrornas confer robustness to gene expression and have a significant impact on 3'utr evolution. Cell 2005, 123, 1133-1146.
145. Dews, M.; Homayouni, A.; Yu, D.; Murphy, D.; Sevignani, C.; Wentzel, E.; Furth, E.E.; Lee, W.M.; Enders, G.H.; Mendell, J.T., et al. Augmentation of tumor angiogenesis by a mycactivated microrna cluster. Nat. Genet. 2006, 38, 1060-1065.
146. O'Donnell, K.A.; Wentzel, E.A.; Zeller, K.I.; Dang, C.V.; Mendell, J.T. C-myc-regulated micrornas modulate e2f1 expression. Nature 2005, 435, 839-843.
147. Hayashita, Y.; Osada, H.; Tatematsu, Y.; Yamada, H.; Yanagisawa, K.; Tomida, S.; Yatabe, Y.; Kawahara, K.; Sekido, Y.; Takahashi, T. A polycistronic microrna cluster, mir-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005, 65, 9628-9632.
148. He, L.; Thomson, J.M.; Hemann, M.T.; Hernando-Monge, E.; Mu, D.; Goodson, S.; Powers, S.; Cordon-Cardo, C.; Lowe, S.W.; Hannon, G.J., et al. A microrna polycistron as a potential human oncogene. Nature 2005, 435, 828-833.
149. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A., et al. Microrna expression profiles classify human cancers. Nature 2005, 435, 834-838.
150. Benetti, R.; Gonzalo, S.; Jaco, I.; Munoz, P.; Gonzalez, S.; Schoeftner, S.; Murchison, E.; Andl, T.; Chen, T.; Klatt, P., et al. A mammalian microrna cluster controls DNA methylation and telomere recombination via rbl2-dependent regulation of DNA methyltransferases. Nat. Struct. Mol. Biol. 2008, 15, 268-279.
151. Sinkkonen, L.; Hugenschmidt, T.; Berninger, P.; Gaidatzis, D.; Mohn, F.; Artus-Revel, C.G.; Zavolan, M.; Svoboda, P.; Filipowicz, W. Micrornas control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nat. Struct. Mol. Biol. 2008, 15, 259-267.
152. Chan, J.A.; Krichevsky, A.M.; Kosik, K.S. Microrna-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65, 6029-6033.
153. Chandra, R.K.; Bentz, B.G.; Haines, G.K., III; Robinson, A.M.; Radosevich, J.A. Expression of glutathione s-transferase pi in benign mucosa, barrett's metaplasia, and adenocarcinoma of the esophagus. Head Neck 2002, 24, 575-581.
154. Voorhoeve, P.M.; le Sage, C.; Schrier, M.; Gillis, A.J.; Stoop, H.; Nagel, R.; Liu, Y.P.; van Duijse, J.; Drost, J.; Griekspoor, A., et al. A genetic screen implicates mirna-372 and mirna-373 as oncogenes in testicular germ cell tumors. Cell 2006, 124, 1169-1181.
155. Eis, P.S.; Tam, W.; Sun, L.; Chadburn, A.; Li, Z.; Gomez, M.F.; Lund, E.; Dahlberg, J.E. Accumulation of mir-155 and bic rna in human b cell lymphomas. Proc. Natl. Acad. Sci. USA 2005, 102, 3627-3632.
156. Iorio, M.V.; Ferracin, M.; Liu, C.G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M., et al. Microrna gene expression deregulation in human breast cancer. Cancer Res. 2005, 65, 7065-7070.
157. Tam, W.; Dahlberg, J.E. Mir-155/bic as an oncogenic microrna. Genes Chromos. Cancer 2006, 45, 211-212.
158. Saito, Y.; Liang, G.; Egger, G.; Friedman, J.M.; Chuang, J.C.; Coetzee, G.A.; Jones, P.A. Specific activation of microrna-127 with downregulation of the proto-oncogene bcl6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9, 435-443.
159. Yoo, C.B.; Jones, P.A. Epigenetic therapy of cancer: Past, present and future. Nat. Rev. Drug Discov. 2006, 5, 37-50.
160. Weber, M.; Baker, M.B.; Moore, J.P.; Searles, C.D. Mir-21 is induced in endothelial cells by shear stress and modulates apoptosis and enos activity. Biochem. Biophys. Res. Commun. 2010, 393, 643-648.
161. Ji, R.; Cheng, Y.; Yue, J.; Yang, J.; Liu, X.; Chen, H.; Dean, D.B.; Zhang, C. Microrna expression signature and antisense-mediated depletion reveal an essential role of microrna in vascular neointimal lesion formation. Circ. Res. 2007, 100, 1579-1588.
162. Tatsuguchi, M.; Seok, H.Y.; Callis, T.E.; Thomson, J.M.; Chen, J.F.; Newman, M.; Rojas, M.; Hammond, S.M.; Wang, D.Z. Expression of micrornas is dynamically regulated during cardiomyocyte hypertrophy. J. Mol. Cell Cardiol. 2007, 42, 1137-1141.
163. Wang, Y.; Lee, C.G. Microrna and cancer--focus on apoptosis. J. Cell Mol. Med. 2009, 13, 12-23.
164. Zeng, L.; Carter, A.D.; Childs, S.J. Mir-145 directs intestinal maturation in zebrafish. Proc. Natl. Acad. Sci. USA 2009, 106, 17793-17798.
165. Wang, X.; Zhao, Q.; Matta, R.; Meng, X.; Liu, X.; Liu, C.G.; Nelin, L.D.; Liu, Y. Inducible nitric-oxide synthase expression is regulated by mitogen-activated protein kinase phosphatase-1. J. Biol. Chem. 2009, 284, 27123-27134.
166. Bui-Nguyen, T.M.; Pakala, S.B.; Sirigiri, D.R.; Martin, E.; Murad, F.; Kumar, R. Stimulation of inducible nitric oxide by hepatitis b virus transactivator protein hbx requires mta1 coregulator. J. Biol. Chem. 2010, 285, 6980-6986.
167. Bernstein, B.E.; Meissner, A.; Lander, E.S. The mammalian epigenome. Cell 2007, 128, 669-681.
168. Chan, G.C.; Fish, J.E.; Mawji, I.A.; Leung, D.D.; Rachlis, A.C.; Marsden, P.A. Epigenetic basis for the transcriptional hyporesponsiveness of the human inducible nitric oxide synthase gene in vascular endothelial cells. J. Immunol. 2005, 175, 3846-3861.
169. Goldberg, A.D.; Allis, C.D.; Bernstein, E. Epigenetics: A landscape takes shape. Cell 2007, 128, 635-638.
170. Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693-705.
171. Allis, C.D.; Berger, S.L.; Cote, J.; Dent, S.; Jenuwien, T.; Kouzarides, T.; Pillus, L.; Reinberg, D.; Shi, Y.; Shiekhattar, R., et al. New nomenclature for chromatin-modifying enzymes. Cell 2007, 131, 633-636.
172. Yang, X.J.; Seto, E. The rpd3/hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 2008, 9, 206-218.
173. Smith, B.C.; Hallows, W.C.; Denu, J.M. Mechanisms and molecular probes of sirtuins. Chem. Biol. 2008, 15, 1002-1013.
174. Wang, G.G.; Allis, C.D.; Chi, P. Chromatin remodeling and cancer, part I: Covalent histone modifications. Trends Mol. Med. 2007, 13, 363-372.
175. Sengupta, N.; Seto, E. Regulation of histone deacetylase activities. J. Cell Biochem. 2004, 93, 57-67.
176. Stamler, J.S.; Singel, D.J.; Loscalzo, J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992, 258, 1898-1902.
177. Yang, X.J.; Gregoire, S. Class ii histone deacetylases: From sequence to function, regulation, and clinical implication. Mol. Cell Biol. 2005, 25, 2873-2884.
178. Lin, J.; Handschin, C.; Spiegelman, B.M. Metabolic control through the pgc-1 family of transcription coactivators. Cell Metab. 2005, 1, 361-370.
179. Fraga, M.F.; Esteller, M. DNA methylation: A profile of methods and applications. BioTechniques 2002, 33, 632, 634, 636-649.
180. Singal, R.; Ginder, G.D. DNA methylation. Blood 1999, 93, 4059-4070.
181. Nestor, C. Enzymatic approaches and bisulfite sequencing cannot distinguish between 5- methylcytosine and 5-hydroxymethylcytosine in DNA. BioTechniques 2010, 48, 317-319.
182. Chan, Y.; Fish, J.E.; D'Abreo, C.; Lin, S.; Robb, G.B.; Teichert, A.M.; Karantzoulis-Fegaras, F.; Keightley, A.; Steer, B.M.; Marsden, P.A. The cell-specific expression of endothelial nitric-oxide synthase: A role for DNA methylation. J. Biol. Chem. 2004, 279, 35087-35100.
183. Guillot, P.V.; Liu, L.; Kuivenhoven, J.A.; Guan, J.; Rosenberg, R.D.; Aird, W.C. Targeting of human enos promoter to the hprt locus of mice leads to tissue-restricted transgene expression. Physiol. Genomics 2000, 2, 77-83.
184. Teichert, A.M.; Miller, T.L.; Tai, S.C.; Wang, Y.; Bei, X.; Robb, G.B.; Phillips, M.J.; Marsden, P.A. In vivo expression profile of an endothelial nitric oxide synthase promoter-reporter transgene. Am. J. Physiol. Heart Circ. Physiol. 2000, 278, H1352-1361.
185. Bentz, B.G.; Hammer, N.D.; Radosevich, J.A.; Haines, G.K., III Nitrosative stress induces DNA strand breaks but not caspase mediated apoptosis in a lung cancer cell line. J. Carcinog. 2004, 3, 16.
186. Radosevich, J.A.; Elseth, K.M.; Vesper, B.J.; Tarjan, G.; Haines, G.K., III Long-term adaptation of lung tumor cell lines with increasing concentrations of nitric oxide donor. Open Lung Cancer J. 2009, 2, 35-44.
187. Vesper, B.J.; Elseth, K.M.; Tarjan, G.; Haines, G.K., III; Radosevich, J.A. Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide. Tumor. Biol. 2010, 31, 267-275.
188. Ridnour, L.A.; Thomas, D.D.; Donzelli, S.; Espey, M.G.; Roberts, D.D.; Wink, D.A.; Isenberg, J.S. The biphasic nature of nitric oxide responses in tumor biology. Antioxid. Redox. Signal 2006, 8, 1329-1337.
189. Wink, D.A.; Mitchell, J.B. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med. 1998, 25, 434-456.
190. Schetter, A.J.; Heegaard, N.H.; Harris, C.C. Inflammation and cancer: Interweaving microrna, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31, 37-49.